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Abstract
Background
Infectious diseases elimination and eradication have become important areas of focus for
global health and countries. Due to the substantial up-front investments required to elimi-
nate and eradicate, and the overall shortage of resources for health, economic analysis can
inform decision making on whether elimination/eradication makes economic sense and on
the costs and benefits of alternative strategies. In order to draw lessons for current and fu-
ture initiatives, we review the economic literature that has addressed questions related to
the elimination and eradication of infectious diseases focusing on: why, how and for whom?
Methods
A systematic review was performed by searching economic literature (cost-benefit, cost-ef-
fectiveness and economic impact analyses) on elimination/eradication of infectious dis-
eases published from 1980 to 2013 from three large bibliographic databases: one general
(SCOPUS), one bio-medical (MEDLINE/PUBMED) and one economic (IDEAS/REPEC).
Results
A total of 690 non-duplicate papers were identified from which only 43 met the inclusion cri-
teria. In addition, only one paper focusing on equity issues, the “for whom?” question, was
found. The literature relating to “why?” is the largest, much of it focusing on how much it
would cost. A more limited literature estimates the benefits in terms of impact on economic
growth with mixed results. The question of how to eradicate or eliminate was informed by an
economic literature highlighting that there will be opportunities for individuals and countries
to free-ride and that forms of incentives and/or disincentives will be needed. This requires
government involvement at country level and global coordination. While there is little doubt
that eliminating infectious diseases will eventually improve equity, it will only happen if ac-
tive steps to promote equity are followed on the path to elimination and eradication.
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Conclusion
The largest part of the literature has focused on costs and economic benefits of elimination/
eradication. To a lesser extent, challenges associated with achieving elimination/eradica-
tion and ensuring equity have also been explored. Although elimination and eradication are,
for some diseases, good investments compared with control, countries’ incentives to elimi-
nate do not always align with the global good and the most efficient elimination strategies
may not prioritize the poorest populations. For any infectious disease, policy-makers will
need to consider realigning contrasting incentives between the individual countries and the
global community and to assure that the process towards elimination/eradication
considers equity.
Introduction
The major global health achievements of the last century were possible due to improvements in
health technologies and services consequent to advances in knowledge, science and technology,
building on improvements in socio-economic conditions [1, 2]. The links between health im-
provements and socio-economic development are well established and the relationship is com-
plex and bi-directional. For example, increasing incomes, education and other forms of social
development improve living conditions and reduce risks to health. They allow people to take
more responsibility for, and invest in their own health. On the other hand, improved health
also allows people to earn more and improve their own living standards [3–7]. There is no
doubt, however, that increased coverage of many types of health interventions—vaccines, safe
childbirth delivery, treatment for tuberculosis, malaria and HIV/AIDS and prevention of car-
diovascular disease to name a few—have also contributed to worldwide health improvements.
Economic analysis has facilitated a better understanding of the relationship between eco-
nomic growth and health, but has also helped to make the case that investments in health pro-
duce excellent returns not just in terms of improved morbidity and mortality but also through
their impact on the economic wellbeing. Economic analysis has now been extended to ques-
tions surrounding one of the most pressing global health challenges: should countries press for
the elimination and eradication of infectious diseases and if so, how? Partly because of the
heavy initial investments required, there are a number of areas in which economics can inform
these important decisions.
We, therefore, undertook a systematic review of the literature to explore how economic
analysis has to date contributed to inform the debate about the elimination/eradication of dif-
ferent infectious diseases. We focus particularly on whether there are common strands across
diseases in the way this analysis has sought to answer three questions: why eliminate, how, and
for whom? [8].
The context: infectious diseases elimination/eradication
The proportion of the global burden of disease attributable to infectious diseases has decreased
considerably in the last two decades [9]. The reasons for this are beyond the scope of this
paper, but are complex and linked to improved socio-economic conditions, disease control
technologies, and increased political will to reduce the burden of infectious diseases [10, 11].
Disease elimination has been defined as a reduction to zero of the incidence of infection
caused by a pathogen in a defined geographical area, while eradication is a permanent
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reduction to zero of the global incidence [12]. Interventions are needed after elimination to
prevent the reestablishment of transmission but, in principle, no longer needed
after eradication.
Elimination and eradication are biologically feasible when there are safe and effective tools
able to interrupt transmission; no animal or environmental reservoirs; adequate public health
and health system infrastructures, sufficient funding and sustained political/societal will are
also required [13].
The investments needed in the early years of elimination/eradication are generally much
larger than those involved in running a routine control programme so economics, a science of
choice in the face of limited resources, can contribute to inform decisions.
Polio eradication is close to being achieved and a plan for the eradication of measles and ru-
bella is under development [14, 15]. Malaria is another disease where eradication has re-
emerged as a global goal [16]. The vision of eliminating and eradicating selected neglected
tropical diseases (NTDs) has also gathered momentum over recent years. In 2011, the WHO
Strategic and Technical Advisory Group for Neglected Tropical Diseases and its partners
adopted a roadmap for the elimination and eradication of 12 NTDs by 2020—rabies, blinding
trachoma, endemic treponematoses, leprosy, chagas disease, human african trypanosomiasis,
visceral leishmaniasis, dracunculiasis, lymphatic filariasis, onchocerciasis, schistosomiasis, and
dengue [17].
Methods
Search strategy and selection criteria
We conducted a systematic literature review in April 2013 of articles published between 1980
and the end of March 2013 retrieved from a bio-medical (PubMed/Medline), a general (SCO-
PUS) and an economic (IDEAS—a Research Papers in Economics, REPEC—hosted service)
database. The year in which smallpox was declared eradicated, 1980, was considered as a con-
venient starting year for this review because economists started to be increasingly interested in
disease elimination thereafter.
Different search strategies were used in the bio-medical, general and in economic databases.
Key words used in the first case were: ((eliminat OR eradicat) AND (cost OR economic)). In
the second case key words used were: (eliminate OR eradicate).
When the same research appeared both as working paper and as article, the latter was select-
ed. Conference proceedings, comments and letters were excluded from the search. From the
extracted articles only economic studies focused on the elimination/eradication of infectious
diseases affecting human populations were selected (Fig 1). For equity issues a separate search
was conducted with the words (equity) AND (eliminat OR eradicat) in all databases.
Results
Summary of studies
A total of 690 articles were identified after discarding 189 duplicates. Papers on Helicobacter
pylori, Staphylococcus aureus and Streptococcus were discarded because they referred to elimi-
nation/eradication in individuals or small communities; so were papers on non-infectious and
non-human infectious disease. That left only 38 articles, but their bibliographies revealed an-
other 5 that had not been found in the initial search. Fig 1 summarises this search.
In the case of equity only one article, which was extracted both from SCOPUS and PubMed
data bases, met the inclusion criteria. This search was not included in Fig 1.
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The results of the literature review were organized by the three key questions described ear-
lier: why, how and for whom to eliminate or eradicate? [8]. The studies dealing with the “why”
question compare costs with benefits. The “how” question assesses which intervention/s or
strategy/ies should be adopted using economic criteria; how to generate incentives for each
Fig 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Diagram.
doi:10.1371/journal.pone.0130603.g001
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country to eliminate; how many resources would be required; and how these resources could
be mobilized. The “for whom” question assesses who would benefit from eradication, and the
likely impact on equity and fairness.
We also classified the papers according to the type of economic issues that were considered:
• Impact of elimination/eradication on GDP growth or on its determinants—social and
human capital accumulation
• Theoretical analyses using game theory
• Financial and economic costs of elimination/eradication
• Cost-benefit or cost-effectiveness analyses.
The articles aimed at assessing the impact of disease elimination/eradication on economic
growth/development were analysed tabulating the following aspects:
• Main hypothesis tested/research question
• Main findings
• Type of study
• Approach used
• Methodology
• Counterfactual
The articles classified as costing studies, cost-benefit and cost-effectiveness analyses were
analysed tabulating the following aspects:
• Hypothesis tested
• Main findings
• Perspective of analysis
• Costs included
• Economic benefits measured
• Health outcomes measured
Articles exploring the question “how to eliminate/eradicate” were analysed tabulating two
main aspects: role of incentives and financial issues associated with elimination/eradication.
Review or opinion articles that we found during the literature search were not tabulated but
we draw on them in the introduction and discussion sections of this manuscript.
Why eliminate or eradicate?
Elimination and eradication are associated with high risks of failure in terms of disease re-
emergence and require substantially higher investments than routine control activities at least
initially. The health and economic benefits therefore need to be higher to justify the higher
costs in the context of scarce resources and competing health problems [18]. There is consider-
able uncertainty about the time path, costs and outcomes of elimination and eradication strate-
gies, so a number of studies have developed cost estimates for a number of different scenarios
[19]. The various authors have also used varying methodologies in estimating costs and bene-
fits, such as the extent to which they have discounted future benefits which accrue in
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perpetuity, and in the treatment of intangible costs and benefits such as anxiety or pain associ-
ated with an elimination program and the benefit of the security when a health risk no longer
exists [20, 21].
To take a complete economic view of elimination/eradication would require a cost-benefit
or cost-effectiveness analysis [22], but many of the studies reviewed did not undertake a com-
plete assessment (Table 1). For example, many considered only the costs of elimination—as in
the case of lymphatic filariasis either in specific countries or globally [23–25]; HIV in South Af-
rica [26]; schistosomiasis from the Guangxi region in China [27]; visceral leishmaniasis in Ban-
gladesh, India and Nepal [28]; and leprosy globally [29]. For malaria, Sabot et al. presented the
first attempt to model costs and benefits of elimination campaigns using data from eight case
studies. The probability that elimination would be cost-saving compared to control ranged
from 0% to 42% [22]. This does not mean that elimination should be rejected as an option be-
cause it would bring many health benefits to the affected populations, but only that it will not
be “self-financing” in the long run.
Several economic evaluations of global measles eradication or elimination indicate that the
strategies are either cost-effective or cost-beneficial compared to routine immunization and
mortality reduction campaigns [30–33]. These studies found that the benefit consequent to
measles elimination or eradication applied to high and middle income (particularly Latin
American) countries as well as to low income countries. For the former, the benefit consisted
in not having to manage responses to imported measles cases; for the latter the benefit con-
sisted in ending the need to conduct resource-intensive mortality reduction campaigns after
eradication. Bishai et al. disputed the idea that measles eradication and elimination were cost-
effective for low- and middle-income countries if they acted by themselves. An important rea-
son why the global benefits of elimination and eradication outweigh the costs is because they
prevent the high costs currently associated with identifying and treating imported cases of mea-
sles in high-income countries. An economic analysis from the perspective of the lower income
countries themselves is less clear cut [34]. The implication is that globally it would make eco-
nomic sense to eradicate measles, but low and middle income countries may have limited in-
centive to do so by themselves because an important part of the returns to their investments
would accrue to high income countries.
The eradication of dracunculiasis has been estimated to have a high return on investment
(29%) [35], and elimination of visceral leishmaniasis in Nepal was estimated to have an even
higher return (35%) [36]. The benefit-cost ratio of the elimination of varicella in Germany was
estimated to be 4.12 (estimates above 1 imply the investment is worthwhile on economic
grounds) [37]. Elimination and eradication of lymphatic filariasis (LF) was found to be less
cost-effective than control in the short term [33] although the lifetime economic benefits of re-
duced treatment in the first eight years of a Global Programme to Eliminate LF were estimated
to be US$ 21.8 billion [24].
The studies reported here were based on models of what would happen if a disease was elim-
inated or eradicated. Few diseases have been eliminated or eradicated in practice, so we could
find only one economic study, dated 1986, of actual elimination (of malaria from Sardinia).
The same study also examined the past attempts to eliminate malaria in Sri-Lanka [38].
As we stated earlier, the reductions in treatment costs that would result from elimination or
eradication are only one part of the potential economic benefits. Few studies tried to estimate
the impact of elimination or eradication on economic growth through the effects on human
capital accumulation (Table 2). In most of these studies elimination programmes are retrospec-
tively used as quasi-natural experiments with the aim of identifying the causal relationship be-
tween health improvements and subsequent economic growth [39–44]. Where studies looked
at the impact of past malaria or hookworm elimination campaigns on the incomes of
Economics and Disease Elimination and Eradication
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Table 2. Why to eliminate/eradicate: The impact of elimination/eradication on economic development, human capital accumulation.
Study and
Year
Hypothesis tested/Research
question Content
Main Findings Counterfactual Approach Methodology used Positive
Economic
impact
identiﬁed?
Brown,
1986 [38]
Relationship between malaria
eradication, population growth
and economic development,
represented by crop
production, in Sardinia and Sri-
Lanka
Effect of malaria eradication
on population growth but not
on economic development
Outcomes in Non-malaria
areas in the two islands
Macro looking at
aggregate trends
Before and after study No
Bleakley,
2007 [43]
Economic impact of successful
eradication of hookworm
disease in the American South
Areas with higher levels of
hookworm infection
experienced greater increase
in school enrolment,
attendance and literacy after
intervention, even by
controlling for relevant factors.
Affected cohorts showed
income gains that coincided
with exposure to hookworm
eradication in the long term.
Eradication increased return to
schooling
Differential outcomes of
cohort of low-infection
areas
Micro, individual
level combined to
construct panel of
average
outcomes by
cohort
Quasi-experimental
econometric identiﬁcation
strategy
Yes
Bleakley,
2010 [42]
Impact of malaria-eradication
campaigns in the USA (1920)
and in Brazil, Colombia and
Mexico (1955) on labour
productivity and income of
children exposed to malaria
during adulthood
Relative to those of malaria
free areas, cohorts born after
eradication campaigns had
higher income as adults than
preceding generation. These
changes coincided with
childhood exposure to the
campaigns rather than to pre-
existing trends
Differential outcomes of
cohorts born in malaria
free areas
Micro, individual
level
Quasi-experimental
econometric identiﬁcation
strategy
Yes
Lucas,
2010 [44]
Impact of malaria eradication
campaigns in Paraguay and
Sri-Lanka on lifetime female
education attainment
Regions with the highest pre-
eradication malaria rates
experienced the largest gains
in education (years of
completed schooling or
literacy). Reducing malaria
incidence by 10% leads to an
increase in completed
schooling of 0.1 years and an
increase in the probability of
being literate by 1%
Differential outcomes of
Low-infection areas
Micro, individual
level
Quasi-experimental;
identiﬁcation strategy
Difference-in-difference
analysis
Yes
Cutler,
2010 [41]
Analysis of the effects of
childhood exposure to malaria
national eradication campaign
in India in the 50s on human
capital accumulation and
income in adulthood.
The program led to either
modest increase in income for
prime age men or to no
improvement for women
suggesting that observed
effects were likely driven by
increased labour market
productivity. No evidence was
found of increased educational
attainment for men, and mixed
evidence for women
Differential outcomes of
Low-infection areas
Micro, individual
level
Quasi-experimental
econometric identiﬁcation
strategy; Difference-in-
difference analysis
Yes, although
limited
Lucas,
2011 [39]
Impact of malaria elimination
campaign on fertility in Sri-
Lanka in the 40s
Malaria elimination increased
fertility due to both improved
child survival and to a change
in preferences. Fertility
increases can cause a
reduction in Gross Domestic
Product (GDP) per capita as
the size of the non-productive
segment of the population
increases. Malaria eradication
increased female educational
attainment and the net effect
on GDP per capita of
education and fertility effect
should be positive, but are not
visible in the short term
Low-infection areas Micro, individual
level
Quasi-experimental
identiﬁcation strategy;
Difference-in-difference
analysis
Yes, although
delayed
(Continued)
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individuals or households as opposed to economies as a whole, the results are conflicting,
sometimes suggesting higher earnings and literacy rates or years of schooling in adults born
after malaria elimination campaigns and sometimes results show no significant effects.
Some studies suggest a possible dilemma resulting from eradication/elimination. If life ex-
pectancy increases, GDP per capita could fall unless the increase in GDP associated with a larg-
er labour force was sufficient to offset the increase in population [39]. However, focusing on
the impact of the size of the labour force on GDP through the effect of elimination/eradication
on life expectancy may not always be appropriate [6]. Some health improvements may not lead
to a longer life but may improve quality of life and hence the productivity of people who work.
Hookworm infection is a case in point. Eliminating hookworm disease has been shown to
make children learn quicker in school and increase their incomes later in life [43]. However, it
does not increase life expectancy. Nevertheless, improving health without affecting life expec-
tancy may still provide a large economic pay-off and a focus on life expectancy may miss this.
When studying the impact of a malaria eradication campaign in Colombia, Bleakey noted that
the elimination of Plasmodium vivaxmalaria led to more significant gains in human capital
and income than the elimination of Plasmodium falciparum, even though falciparum causes
more deaths than vivax [42].
The effects of malaria elimination campaigns on selected non-health drivers of economic
growth have also been studied. The effect on tourism was estimated for Mauritius and the Do-
minican Republic. At the national level, and after accounting for several possible confounding
factors, the impact was small and not significant [45]. From a macro-economic point of view it
Table 2. (Continued)
Study
and Year
Hypothesis tested/
Research question
Content
Main Findings Counterfactual Approach Methodology used Positive
Economic
impact
identiﬁed?
Barofsky,
2011 [40]
This study evaluates the
economic consequences of
a malaria eradication
campaign (1959–60) in the
South Western Ugandan
district of Kigezi
Eradication produced
differential improvements
in Kigezi compare to the
rest of Uganda in years of
schooling, literacy, and
primary school completion.
In addition, eradication
increased income levels
Differential outcomes
before and after the
Campaign of areas in
Uganda where the
campaign was not
carried out
Micro,
individual level
Quasi-experimental
identiﬁcation strategy;
Difference-in-
difference
Yes
Hulden,
2012 [70]
Analysis of the association
between malaria
elimination and household
size for 188 countries
When the average
household size drops
below 4 persons the
probability of malaria
eradication jumps
dramatically and its
incidence in the population
drops signiﬁcantly
Micro- Country
level
Instrumental variables
approach
Yes
Modrek,
2012 [45]
This study examines the
empirical relationship
between the demand for
travel and malaria cases in
two countries (Mauritius
and Dominican Republic)
around the time in which
malaria-elimination
campaigns were carried
out
The relationships between
tourist arrivals and malaria
cases were statistically
insigniﬁcant once
confounders were
accounted for, suggesting
that any economic beneﬁts
from tourism derived from
elimination programs are
likely to be small when
measured at a national
level
No counterfactual Micro Time series methods
to explain the
logarithm of number of
tourists in time as a
function of the
logarithm of number of
malaria cases
Yes, but
limited
doi:10.1371/journal.pone.0130603.t002
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has been argued that there was little impact of malaria elimination on GDP growth and that
other factors, such as technological change and human capital accumulation, were the major
drivers of the escape from poverty in the South of Europe in the fifties [46].
How to eliminate and eradicate?
Regional elimination and global eradication imply collective decision making, where several
stakeholders have to decide on issues of collective interest in a context of different preferences
and endowments. As part of the broad economic analysis, social choice theory is the study of
collective decision processes and outcomes and game theory studies the strategic interdepen-
dence of individual choices and the design of collective choice rules to implement socially opti-
mal decisions [47]. These approaches could be used to assess the success probabilities, or the
impact, of different elimination or eradication strategies, to better inform a global or regional
decision—e.g. should the strategy start by focusing on areas of the most intense transmission
before moving to other areas? Our search did not reveal any examples of this type of analysis.
However, there has been some theoretical work focused on how to encourage all of the affected
countries to move towards eradication or elimination (Table 3) [19, 48–51].
These studies recognize that most infectious diseases are cross-border issues and that once a
disease is eradicated, all countries benefit independently from their individual contributions
(the public good concept). However, in order to achieve eradication (or regional elimination)
all affected countries need to take actions. For countries that share borders the success of elimi-
nation depends also on the decision of the neighbors to eliminate.
Starting from a rationality assumption where stakeholders take decisions aimed at maximiz-
ing their net benefits, there are four possible outcomes:
a. The net benefits of eradication for the whole world or for the countries involved in regional
elimination may be negative, making control the chosen option for everyone;
b. The net benefits of elimination may be so high that every country chooses to eliminate a dis-
ease unilaterally, making eradication or regional elimination the universal choice;
c. It may not be worthwhile for any country to eliminate the disease unilaterally given that oth-
ers have not eliminated the disease. It may also not be worthwhile for any country to elimi-
nate the disease once all others have done so. In this case, eradication or regional
elimination is a “coordination” game. There are two possible outcomes: in one, no country
eliminates; in the other, every country eliminates the disease and eradication is achieved. To
tip the balance towards eradication, each country would need to be convinced that all other
countries will eliminate and not try to free ride on the efforts of others;
d. It may not be worthwhile for the last country to eliminate a disease after all others have
done so, and yet the net benefits of eradication may be positive to the world as a whole. In
this case, incentives or disincentives aimed at the recalcitrant country would need to
be developed.
Given that options c) and d) are the most likely, researchers are exploring if forms of global
governance or international regulation within the field of international law might be appropri-
ate [52]. The other option is that the richer countries will need to pay for the elimination efforts
in poorer countries or in countries that do not choose to do it voluntarily, as happened for
smallpox eradication [49].
Within country borders, the elimination of an infectious disease implies increasing the de-
mand for preventative measures, such as vaccines. In this case, incentives are needed to raise
immunization coverage that allows blocking transmission of the infection. Bahram et al.
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Table 3. How to eliminate/eradicate: the role of incentives and financial issues.
Study and
year
Type of study and content Incentives Financial issues
Barrett,
2004 [48]
Policy paper/review As beneﬁt can be much higher than costs,
the incentives for countries to participate in
an eradication initiative can be strong.
Based on the smallpox experience, poor
countries that may trying to eliminate might
fail due to lack of expertise. Thus,
eradication may require international
cooperation on top of coordination. In
some cases, the incentive to eliminate may
depend on each country being assured
that all other countries would eliminate. For
this, eradication may require third party
enforcement.
If poor countries are either unable or they lack
the incentive to eliminate a disease on their
own or as part of a coordinated effort, rich
countries might have an incentive to ﬁnance
the global eradication program. This way, rich
countries would earn a return on their
investment, making poor countries also better
off.
Barrett,
2006 [49]
Policy paper on smallpox eradication According to costs and beneﬁts of
eradication, the rich countries had an
incentive to eliminate smallpox unilaterally.
Many poor countries, such as India, also
had an incentive to eliminate unilaterally,
but lacked the capability to do so.
International assistance was needed.
The weakest link nature of eradication, and
the very high beneﬁt-cost ratio (over 400:1),
translate into developed country ﬁnancing of
elimination in developing countries. This could
be achieved by coordination.
Barrett,
2007 [50]
Theoretical paper where a general
epidemiology model is linked with the
optimization model (constraint maximization
of a socially efﬁcient vaccination program)
A full global cost—beneﬁt analysis is
needed to determine whether eradication
is a good deal overall. Being eradication
an extreme goal, the analysis of an
eradication program needs to begin from
the perspective of where the program will
end, thus from the “last mile”.
NA
Barrett,
2011 [51]
Theoretical paper on polio, modelling the
cessation of vaccination after eradication
linking a epidemiology, a risk of re-
emergence and an economic model
The incentives to eradicate polio are
closely linked to the post-eradication
game. Equilibrium strategies and efﬁcient
outcomes are deﬁned for different level of
incentives and under different conditions
NA
Barham
et al, 2009
[53]
Impact evaluation of conditional cash
transfer program in Nicaragua to rise
vaccination coverage towards a level that
would be required for eradication (95% for
measles, for instance)
The study ﬁnds that effects are particularly
large for the children who are hard-to-
reach with traditional supply-side
interventions.
NA
Chesson
et al, 2008
[55]
The paper evaluates the impact of greater
amounts of state-level funding for syphilis
elimination on syphilis rates in subsequent
years in the US
NA Higher level of funding, speciﬁcally, federally-
funded syphilis elimination activities have a
notable impact on syphilis rates
Geoffard
et al, 1997
[54]
Theoretical paper analysing the contribution
towards disease eradication of public and
private interventions to increase vaccination
coverage
From the public perspective, both price
subsidies and mandatory vaccination
programs have limited ability to achieve
eradication because the increase in
demand of individuals covered by the
programs lowers the incentive to vaccinate
for those outside the program. From the
private perspective, price subsidies may
make it potentially proﬁtable for a
monopolist to eradicate the disease.
However, a vaccine monopolist faces a
nonstandard dynamic incentive to increase
markups, limiting the demand for the
monopolist's product.
A deﬁcit-ﬁnanced eradication program, which
spends beyond tax revenues but recoups the
deﬁcit in future generations, may improve
welfare. In fact, such a program would allow
for the intergenerational transfers that are
necessary to pay current generations to over-
vaccinate for the beneﬁt of future generations,
which although beneﬁt, do not compensate
the vaccine manufacturers.
doi:10.1371/journal.pone.0130603.t003
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evaluated a randomized experiment showing that cash incentives paid to mothers increased
vaccination coverage to 95% in rural Nicaragua [53]. Theoretical work by Geoffard and Philip-
son analyzed the difficulties of achieving disease eradication through vaccination using various
types of incentives, highlighting that increased coverage levels reduce the incentive of those not
yet vaccinated because they are less at risk of contracting the disease [54]. Chesson et al. found
that greater amounts of state-level funding for syphilis elimination had a notable impact in
lowering syphilis rates in subsequent years within the context of a national elimination plan in
the US [55].
For whom to eradicate?
In principle, elimination and eradication should resolve the equity/efficiency trade-off inherent
in the scale-up of health interventions, in which efficiency implies quickly providing access to
the easy-to-reach groups (e.g. more affluent groups in urban areas) and equity implies specifi-
cally targeting resources to poor and vulnerable groups who might be harder and more costly
to reach [56]. All infectious diseases that are targeted for elimination are concentrated among
the poor, so elimination/eradication would improve the health of the poor disproportionally.
Disease elimination thus, interpreted through the lens of the social-choice theory described
earlier, can be seen as the realization of an egalitarian policy: policies should aim either at com-
pensating for unequal endowments for which the affected individuals are not responsible or at
equalising certain “capabilities” essential for the preservation of life and the ability to freely
choose one’s own way of life [57, 58]. In this respect, health is both an endowment for which
individuals are at birth not responsible and a crucial constituent of human capabilities.
The literature applying these concepts to disease elimination and eradication is, however,
limited apart from concerns that the process leading to disease elimination may lead to greater
inequity in the short term. This may occur if countries choose to begin expensive elimination
programs in less challenging areas which are usually low transmission areas where people are
more affluent and healthier. The implications for equity may be even higher if elimination fails
so control ends up being more effective in the areas that were relatively affluent initially, a con-
cern that has been expressed for example with malaria elimination programmes [59]. These
concerns seem to be supported by apparent small improvements in equity that have been ob-
served with the scale up of coverage of certain malaria interventions to date, suggesting that the
least affluent and most needy have proved more difficult to cover [60, 61].
Discussion
We have examined the contribution that economic analysis has made to the question of the
elimination/eradication of infectious diseases. Elimination/eradication is particularly interest-
ing because it will require substantial initial investments, more than running routine control
programs. It is also linked to the concept of public good; it will not happen unless all affected
countries take a conscious decision to do it, while at the same time countries have an incentive
to let others pay.
The economic literature relating to “why eliminate/eradicate” is the largest, much of it sug-
gesting that the eventual financial returns could be high—in the long run there might be sub-
stantial savings from not having to treat people or run routine control programs. In some
cases, however, this does not look likely but then there are other economic benefits in terms of
increased economic productivity. A problem in this case is that these additional benefits do not
necessarily accrue to the people who pay for the elimination efforts in the first place, which
make financing elimination/eradication challenging.
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Despite the belief of some public health experts that the economic benefits of investing in
health should not be relevant to public decision-making, which should focus only on human
rights to the highest attainable level of health, we suggest that national governments, global
health policy makers, and donors always need to know how much a proposed course of action
will cost, and what the benefits will be in terms of health and economic wellbeing. We acknowl-
edge the importance of human rights, but it does not help to ignore the fact that resources are
always limited.
Economics has contributed to addressing the question of how to invest in eradication or
elimination by highlighting that there will be incentives for individuals and for countries to
free-ride and that forms of incentives and/or disincentives for this behaviour will need to be de-
veloped. This requires government involvement at country level and global coordination and
cooperation. It will not happen if left to the market or to individual endemic countries to act
alone. While equity should be a key factor to guide the implementation of any health interven-
tion, we found only one article analysing the impact on equity of disease elimination cam-
paigns. However, when complemented with other evidence on the trade-offs between equity
and efficiency in healthcare delivery more generally, this was sufficient to trigger a series of re-
flections. While there is little doubt that eliminating infectious diseases will eventually improve
equity, it is not clear that equity will be improved on the path to elimination and/or eradication
in the short run. Countries will have an incentive to begin with easier-to-reach areas which will
often be those with higher incomes and levels of health, so specific equity strategies would need
to be applied early. An interesting twist to the equity story is currently being provided by mea-
sles where the refusal to have children vaccinated among affluent people in the richest coun-
tries is proving a stumbling block to the final efforts towards eradication. The strategies
adopted on the path to elimination are, therefore, particularly important and must be based
not simply on considerations of cost and cost-effectiveness.
Though this was not the focus of our review, disease eradication/elimination initiatives
clearly need to take into account the broad health system impacts as well which are often diffi-
cult to incorporate into an economic analysis [62, 63]. This is an added dimension that policy-
makers always consider in addition to cost and impacts, and equity.
We found few articles on this aspect, and few eligible articles for this review of the economic
literature in general. No article integrated the different components of costs, benefits, public
good and equity issues. We found, instead, that articles published in public health journals
were more focused on costs and benefits in terms of reduced treatment costs (direct benefits)
while articles published in economic journals concentrated on the impact on household or na-
tional incomes (indirect benefits). None of these strands of literature included equity issues.
Despite this, the literature reviewed provides some evidence of the costs of various elimination/
eradication strategies, the possible impact in terms of treatment costs and sometimes
incomes, and allowed us to draw some important policy conclusions. The most important one
involves the need to understand and realign contrasting incentives between the motivation of
individual countries and the global community if elimination/eradication is to happen. It is
also critical to consider equity on the path to elimination/eradication rather than just at
the end.
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